Arber DA, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, J Am Soc Hematol. 2022;140(11):1200–28.

CAS  Google Scholar 

Bennett JM, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189–99.

Article  CAS  Google Scholar 

Germing U, et al. Problems in the classification of CMML–dysplastic versus proliferative type. Leuk Res. 1998;22(10):871–8.

Article  CAS  Google Scholar 

Neukirchen J, et al. Incidence and prevalence of myelodysplastic syndromes: Data from the Düsseldorf MDS-registry. Leuk Res. 2011;35(12):1591–6.

Article  Google Scholar 

Guru Murthy GS, Dhakal I, Mehta P .Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States. Leukemia Lymphoma. 2017;58(7):1648–1654

Sastow DL, et al. Estimating the Prevalence of Possible Undiagnosed Chronic Myelomonocytic Leukemia in the General Population: An Nhanes Analysis. Blood. 2024;144:5182.

Article  Google Scholar 

Pleyer L, et al. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematol. 2021;8(2):e135–48.

Article  CAS  Google Scholar 

Hunter AM, et al. Integrated human and murine clinical study establishes clinical efficacy of ruxolitinib in chronic myelomonocytic leukemia. Clin Cancer Res. 2021;27(22):6095–105.

Article  CAS  PubMed Central  Google Scholar 

Hiwase D, et al. Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine. Blood. 2024;144:1006.

Article  Google Scholar 

Mannis GN, et al. IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results. Blood. 2024;144:1008.

Article  Google Scholar 

Kishtagari A, et al. Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS/MPN Working Group Study. Blood. 2023;142:1874.

Article  Google Scholar 

Selimoglu-Buet D, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood, J Am Soc Hematol. 2015;125(23):3618–26.

CAS  Google Scholar 

Geyer JT, et al. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. Mod Pathol. 2017;30(9):1213–22.

Article  CAS  Google Scholar 

Khoury JD, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022:36(7):1703–1719

Montalban-Bravo G, et al. Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia. Blood. 2024;144:3204.

Article  Google Scholar 

Carr RM, et al. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun. 2021;12(1):2901.

Article  CAS  PubMed Central  Google Scholar 

Baumgartner F, et al. Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022. Blood. 2024;143(12):1139–56.

Article  CAS  Google Scholar 

Komrokji RS, et al. CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML? Blood. 2024;144(Supplement 1):1004–1004.

Article  Google Scholar 

Venugopal S, et al. Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents. Blood. 2021;138(Supplement 1):2613–2613.

Article  Google Scholar 

Such E, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005–15.

Article  CAS  Google Scholar 

Benton CB, et al. Chronic myelomonocytic leukemia: Forefront of the field in 2015. Crit Rev Oncol Hematol. 2015;95(2):222–42.

Article  PubMed Central  Google Scholar 

Gelsi-Boyer V, et al. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012;5(1):12.

Article  CAS  PubMed Central  Google Scholar 

Gelsi-Boyer V, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151(4):365–75.

Article  CAS  Google Scholar 

Alawieh D, et al. RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives. Blood Cancer J. 2024;14(1):72.

Article  PubMed Central  Google Scholar 

Di J, et al. Prognostic Significance and Treatment Response Associations of Genetic Mutations in Chronic Myelomonocytic Leukemia: A Retrospective Cohort Study. Biomedicines. 2024;12(11):2476.

Article  CAS  PubMed Central  Google Scholar 

Hunter AM, et al. WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State. Blood. 2019:134(Supplement_1):1717–1717

González JS, et al. Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients. Ann Hematol. 2021;100(6):1439–49.

Article  Google Scholar 

Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6(2): e393.

Article  CAS  PubMed Central  Google Scholar 

Wassie EA, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. Am J Hematol. 2014;89(12):1111–5.

Article  CAS  Google Scholar 

Elena C, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408–17.

Article  CAS  PubMed Central  Google Scholar 

Tefferi A, et al. BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia. Blood. 2025

Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024;99(6):1142–65.

Article  CAS  PubMed Central  Google Scholar 

Patnaik MM, Tefferi A. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. Mayo Clin Proc. 2016;91(2):259–72.

Article  Google Scholar 

Padron E, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5(7): e333.

Article  CAS  PubMed Central  Google Scholar 

Onida F, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99(3):840–9.

Article  CAS  Google Scholar 

Worsley A, et al. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol. 1988;68(1):17–21.

Article  CAS  Google Scholar 

Such E, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375–83.

Article  Google Scholar 

Itzykson R, et al. Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. J Clin Oncol. 2013;31(19):2428–36.

Article  CAS  Google Scholar 

Patnaik MM, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28(11):2206–12.

Article  CAS  Google Scholar 

Palomo L, et al. Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia. Blood. 2024;144(Supplement 1):3205–3205.

Article  Google Scholar 

Lanino L, et al. A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML). Blood. 2024;144:1003.

Article  Google Scholar 

Patnaik MM, et al. Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. Am J Hematol. 2018;93(1):65–73.

Article  CAS  Google Scholar 

Bataller A, et al. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Adv. 2024;8(11):2695–706.

Article